Source comparison
Sermorelin vs Direct GH Administration (Comparison)
Mechanism GHRH-R agonist. Stimulates endogenous pituitary GH release Direct hormone replacement. Bypasses pituitary entirely Sermorelin preserves axis function; GH suppresses it Pulse Pattern Maintains natural ultradian rhythm (discrete pulses) Sustained eleva
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH-R agonist. Stimulates endogenous pituitary GH release
- Direct hormone replacement. Bypasses pituitary entirely
- Sermorelin preserves axis function; GH suppresses it
- Pulse Pattern
- Maintains natural ultradian rhythm (discrete pulses)
- Sustained elevation or pharmacokinetic peak-trough curve
- Pulse preservation reduces metabolic adaptation risk
- IGF-1 Response
- 30–40% increase from baseline over 12–16 weeks
- 100–200% elevation within days, dose-dependent
- GH produces supraphysiological IGF-1; sermorelin stays physiological
- Regulatory Status
- Prescription required; not FDA-approved as drug product
- FDA-approved for specific indications (pediatric GHD, adult GHD, AIDS wasting)
- GH has approval pathway; sermorelin is compounded under 503B
- Cost (Monthly)
- $150–$300 for research-grade peptide
- $800–$2,500 for pharmaceutical GH
- Sermorelin is 70–85% less expensive per month
- Pituitary Suppression Risk
- None. Works through endogenous pathway
- High. Exogenous GH suppresses natural GH secretion via negative feedback
- Long-term GH use can atrophy pituitary somatotrophs